Compare GEMI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | AVIR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | 650 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.3M | 434.5M |
| IPO Year | N/A | 2020 |
| Metric | GEMI | AVIR |
|---|---|---|
| Price | $5.17 | $5.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | $8.31 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.5M | 225.6K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | $35.05 | N/A |
| Revenue Next Year | $39.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $2.46 |
| 52 Week High | $34.67 | $6.45 |
| Indicator | GEMI | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 43.96 |
| Support Level | $4.01 | $5.13 |
| Resistance Level | $5.24 | $6.37 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 86.69 | 24.58 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.